KRAS and neoplasm: The AKT/IWS1/U2AF2/CDCA5/ERK pathway is active in human lung adenocarcinomas and impacts tumor grade, stage, metastatic potential, and treatment relapse in patients with EGFR mutant, but not KRAS mutant tumors